Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin versus placebo in neonates and young infants with Prader-Willi syndrome
2019-002385-12Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Intranasal oxytocin with Placebo (2 arms). Primary endpoint: Responder rate on NOMAS sucking/swallowing score at 4 weeks. Started Jun 2019; status: completed.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2019-002385-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002385-12.